DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo


company name or ticker

Perilous Reversal Watch: Orexigen Therapeutics (OREX)

The Implications of Obesity as a Disability in Europe

Despite rising obesity in Europe, the EU has yet to approve weight loss drugs from Arena (ARNA), Vivus (VVUS), or Orexigen (OREX).

Trade-Ideas: Orexigen Therapeutics (OREX) Is Today's "Dead Cat Bounce" Stock

Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Res

Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Arena Pharmaceuticals Inc. Still Down After CEO's Sale

It says something about the short-term prospects for Arena Pharmaceuticals. And competitors, Orexigen and VIVUS, for that matter.

Arena Stock Holds On Expected Dip In Sales - Bottom May Be In

3 Stocks Even Volatility-Loving Nasdaq Investors Hate

The Nasdaq Composite may be hitting a multidecade high, but pessimists are piling into these three Nasdaq-listed stocks. Are things really as bad as these short-interest figures indicate?

The Next Orphan Drug Multibagger and Future Obesity Champion?

Zafgen's arrival on public markets shakes up the obesity drug war

3 Biotech Stocks with Catalysts Incoming: Spectrum, Orexigen, and Avanir

For companies involved in the development of drugs, a PDUFA decision will meaningfully impact their stocks. With this in mind, there are several PDUFA decisions in upcoming months to watch for.

Are Investors Wrong About Orexigen Therapeutics?

Short-sellers are moving into Orexigen Therapeutics ahead of the company's PDUFA date for its flagship obesity drug. Here's why.
See More Articles...